The company has reduced its share count over this period, returning value to shareholders through buybacks.
Diluted shares outstanding: 168.8M (2022) → 162.8M (2026)
FDC Limited, together with its subsidiaries, manufactures and trades in pharmaceutical products in India, the United States, and internationally. The company offers pharmaceutical formulations for various therapeutic segments, including anti-infectives, gastrointestinal, ophthalmology, vitamins, minerals, dietary supplements, cardiovascular and anti-diabetic therapies, respiratory care, gynaecology, dermatology, and analgesics in the form of tablets, capsules, oral liquids, ophthalmic drops, topical preparations, and paediatric-friendly solutions. It also provides functional food, such as flavoured ORS powders, ready-to-drink electrolyte beverages, vitamin-enriched supplements, antioxidant blends and protein-fortified drinks; and various active pharmaceutical ingredients. The company sells its products under the Zifi, Zefu, Zocon, Amodep-AT, Zathrin, Vitcofol, Ziglim, Ziglim-M,Mycoderm, Zoxan, Cotaryl, Pyrimon DF, Zipod, Electral, and Enerzal brands. It also exports its products to approximately 50 countries. FDC Limited was founded in 1936 and is based in Mumbai, India.
When traditional metrics don't capture the full picture, these are the signals growth stock investors use instead.
+3.0% YoY
YoY Growth Rate
Slow revenue growth
+9.3% YoY
YoY Growth Rate
Slow EPS growth
₹0/ year
↓ Declining (-100% vs prior year)
0.0% of revenue
Below sector average (18%)
R&D spend declining — could signal cost-cutting or efficiency
Cash flow positive
₹0 cash & investments
Quarterly Free Cash Flow
Company generates more cash than it spends — no dilution risk from fundraising
FDC Limited is growing revenue at 3% year-over-year. The Winston Score measures business quality today — these growth metrics show what could matter tomorrow.
The Winston Score above measures business quality today. Growth stocks often score lower because they invest in the future rather than maximising current profits. These metrics show what matters most for evaluating that future.
Each metric is explained in plain language so you know exactly what you're looking at. Start your free trial now.
ROIC between 5% and 15%. They earn 5 to 15 cents back per year on every dollar invested.
Full breakdown available with your free trial
See every metric, trend, and what it means for this stock.
Single-digit earnings growth — steady but not exciting.
Full breakdown available with your free trial
See every metric, trend, and what it means for this stock.
Free cash flow is negative. They are burning cash, not generating it.
Full breakdown available with your free trial
See every metric, trend, and what it means for this stock.
Interest coverage above 8. Profits cover interest many times over.
Full breakdown available with your free trial
See every metric, trend, and what it means for this stock.
P/E in the normal range. Price is roughly $15 for every $1 of yearly profit.
Full breakdown available with your free trial
See every metric, trend, and what it means for this stock.
Modest yield. The bulk of any return needs to come from price appreciation.
Full breakdown available with your free trial
See every metric, trend, and what it means for this stock.
